Dr. Sandip B. Bharate

Dr. Sandip B. Bharate

Principal Scientist / HOD of NPMC Division

Natural Products & Medicinal Chemistry Division

CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: sbharate@iiim.res.in

Profile

Bio Sketch

Sandip B. Bharate is a Principal Scientist & Associate Professor (Medicinal Chemistry) at Indian Institute of Integrative Medicine, the constituent laboratory of Council of Scientific and Industrial Research, India. He received M.S. and Ph.D. in Natural Products from the National Institute of Pharmaceutical Education and Research Mohali in 2002 and 2007, respectively. Subsequently, he worked as a Research Scientist at Piramal Life Sciences Ltd, Mumbai for 1.5 years. Following an NIH postdoctoral fellowship with Prof. Charles M. Thompson at the University of Montana (U.S.), he began his independent research career at the Indian Institute of Integrative Medicine in 2011.

His laboratory focuses on the discovery and development of natural products based small-molecule kinase inhibitors. He is the lead inventor of a Cdk inhibitor IIIM-290 which has recently entered a clinical trial. His group is also working on the rational drug design of multi-targeted anti-Alzheimer agents. One of the anti-Alzheimer lead IIIM-141 discovered from his group has been licensed to the industry as a nutraceutical product.

Academic honors to his credit include InnoCentive awards, NASI Platinum Jubilee Young Scientist Award, CSIR Young Scientist award, OPPI Young Scientist Award and MEDI Young Investigator Award 2020 and CSIR Technology Award 2021 (certificate of merit). He has been listed among the World’s top 2% Scientists(Medicinal Chemistry) in the list released by Stanford University in 2020.

Education

Degree Subjects University Qualifying Year
Ph.D. Natural Products NIPER Mohali 2007
M.S. Pharm. Natural Products NIPER Mohali 2002
B. Pharm. Pharmacy University of Pune 2001

Position Held

Position Held

Position Held Period Organization
Principal Scientist & Head 2021-Present Natural Products & Medicinal Chemistry Division,

CSIR-Indian Institute of Integrative Medicine, Jammu, India
Principal Scientist 2015-2021 Medicinal Chemistry Division,

CSIR-Indian Institute of Integrative Medicine, Jammu, India
Scientist Fellow/ Senior Scientist 2011-2015 Medicinal Chemistry Division,

CSIR-Indian Institute of Integrative Medicine, Jammu, India
Post-doctoral Scientist 2008-2010 NIH COBRE Centre for Structural & Functional Neuroscience, The University of Montana, USA.
Research Scientist 2007-2008 Piramal Life Sciences Ltd, Mumbai
Research Chemist 2003-2003 Dr. Reddy’s Laboratories, Hyderabad, India

 

 

Area of Expertise

Area of Expertise

  • Natural products driven drug discovery via employing computational tools, and medicinal chemistry approaches, followed by preclinical and clinical development.
  • Specific interests: Kinase inhibitors (Cancer, Alzheimer’s), Multi-targeted agents (Alzheimer’s)

Project Involved / Ongoing Projects

Projects

  • Preclinical development of crocin-1 enriched Crocus sativus as phytopharmaceutical lead [P90807- CSIR (Young scientist award grant); 2017-2022] – PI
  • Repurposing of colchicine for management of COVID-19 patients [MLP-110002] [2020-2021] – PI
  • Process development for COVID-19 API’s: [2020-21] – PI for one API.
  • Development nutraceutical products from algae [CLP-0309- Industry sponsored project]- co-PI

Publications and Patents

Publications

Complete list of publications can be found at:

https://pubmed.ncbi.nlm.nih.gov/?term=Bharate+SB

Medicinal Chemistry:

Authors Title Journal
Bhurta D, Bharate SB.* Analyzing the Scaffold Diversity of Cyclin-dependent Kinase Inhibitors and Revisiting the Clinical and Preclinical Pipeline Med. Res. Rev. 2021

DOI: 10.1002/med.21856
Raghuvanshi R.; Bharate SB.* Recent developments in the use of kinase inhibitors in management of viral infections J. Med. Chem.  2021, ASAP
Nuthakki VK; Yadav RR; Bharate SB.* Identification of Aplysinopsin as a Blood-brain Barrier Permeable Scaffold for Anti-cholinesterase and Anti-BACE-1 activity Bioorg. Chem. 2021, 107, 104568

 
Abdullaha M; Nuthakki VK; Bharate SB.* Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase Eur. J. Med. Chem., 2020, 207, 112761

 
Abdullaha M; Mohammed S; Ali M; Kumar A; Vishwakarma RA;  Bharate SB* Discovery of Quinazolin-4(3H)-ones as NLRP3 Inflammasome Inhibitors: Computational Design, Metal-free Synthesis and In-vitro Biological Evaluation J. Org. Chem., 2019, 84, 5129-5140
Bharate SB;* Kumar V; Jain SK; Mintoo NJ; Guru SK; Nuthakki VK; Sharma M; Bharate SS; Gandhi SG; Mondhe DM; Bhushan S; Vishwakarma RA. Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-dependent Kinase Inhibitor J. Med. Chem. 2018, 61, 1664-1687
Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB* Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells J. Chem. Inform. Model., 2017, 57, 1309–1320
Bharate SB;* Singh B; Kachler S; Oliveira A; Kumar V; Bharate SS; Vishwakarma RA; Klotz KN; Gutiérrez de Terán H. Discovery of 7-(prolinol-N-yl)-2-phenylamino-thiazolo[5,4-d]pyrimidines as novel non-nucleoside partial agonists for the A2A adenosine receptor: Prediction from molecular modeling J. Med. Chem., 2016, 59, 5922-5928
Sharma R; Patel N; Vishwakarma RA; Bharatam PV; Bharate SB* Metal-free oxidative cyclization of acetophenones with diamines: A facile access to phenylpyridines Chem. Commun., 2016, 52, 1009-1012
Mahale S; Bharate SB;* Manda S; Joshi P; Bharate SS; Jenkins PR; Vishwakarma RA; Chaudhuri B. Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a non-planar analog of fascaplysin inhibits Cdk4 and tubulin polymerization: Evaluation of in vitro and in vivo anticancer activity J. Med. Chem., 2014, 57, 9658-9672
Jain SK; Singh S; Khajuria A; Guru SK; Joshi P; Meena S; Nadkarni J; Singh A; Bharate SS; Bhushan S; Bharate SB*; Vishwakarma RA. Pyrano-isochromanones as IL-6 inhibitors: Synthesis, in-vitro and in-vivo anti-arthritic activity J. Med. Chem., 2014, 57, 7085−7097
Mudududdla R; Sharma R;  Abbat   S; Bharatam PV;  Vishwakarma RA; Bharate SB* Synthesis of 2-phenylnaphthalenes from styryl-2-methoxybenzenes Chem. Commun., 2014, 50, 12076-12079
Bharate SB; Sawant SD; Singh PP; Vishwakarma RA. Kinase inhibitors of marine origin Chem. Rev., 2013, 113, 6761-6815

Natural Products/ phytopharmaceuticals:

Authors Title Journal
Raghuvanshi R, Nuthakki VK, Singh L, Singh B, Bharate SS, Bhatti R, Bharate SB* Identification of Plant-based Multitargeted Leads for Alzheimer’s Disease: In-vitro and In-vivo Validation of Woodfordia fruticosa (L.) Kurz. Phytomedicine, 2021, 91, 153659
Ntemafack A; Nuthakki V; Abdullaha M; Qazi H; Gandhi SG; Bharate SB*. Discovery of Helminthosporin, an Anthraquinone Isolated from Rumex abyssinicus Jacq as a Dual Cholinesterase Inhibitor ACS Omega, 2020, 5 (3), 1616-1624

 
Kumar V; Bharate SS; Bhurta D; Gupta M; Gandhi SG; Singh D; Jaglan S; Kumar A; Vishwakarma RA; Bharate SB* Evaluation of rohitukine-enriched fraction of Dysoxylum binectariferum Hook.f. (leaves) as Anti-arthritic Phytopharmaceutical Candidate: Chemical Standardization, In-vivo validation, Formulation Development and Oral Pharmacokinetics J. Ethnopharmacol., 2020, 254, 112758
Nuthakki VK; Sharma A; Kumar A; Bharate SB* Identification of embelin, a 3-undecyl-1,4-benzoquinone from Embelia ribes as a multitargeted anti-Alzheimer agent Drug Dev. Res., 2019, 80, 655-665
Bharate SB*; Kumar V; Bharate SS; Singh B; Singh GD; Singh A; Gupta M; Singh D; Kumar A; Singh S; Vishwakarma RA. Discovery and preclinical development of IIIM-160, Bergenia ciliata based anti-inflammatory and anti-arthritic botanical drug candidate J. Integr. Med., 2019, 17, 192–204
Bharate SS; Kumar V; Singh GD; Singh A; Gupta M; Singh D; Kumar A; Vishwakarma RA; Bharate SB* Preclinical development of Crocus sativus based botanical lead IIIM-141 for Alzheimer’s disease: Chemical standardization, efficacy, formulation development, pharmacokinetics and safety pharmacology ACS Omega, 2018, 3, 9572−9585
Kumar V; Gupta M; Gandhi SG; Bharate SS; Kumar A; Vishwakarma RA; Bharate SB* Anti-inflammatory chromone alkaloids and glycoside from Dysoxylum binectariferum Tetrahedron Lett. 2017, 58, 3974-3978

Patents

Inventors/ Contributors Title & patent number Description Year
Vishwakarma RA, Bharate SB, Bhushan S, Mondhe DM, Jain SK, Meena S, Guru SK, Pathania AS, Kumar S, Behl A, Mintoo MJ, Bharate SS, Joshi P. Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof. US9932327B2, EP2986605.

 

 Granted in US, EP

 

 2018
Bharate SB, Bhushan S, Mohammed S, Guru SK, Bharate SS, Kumar V, Mahajan G, Javed  MM, Mondhe DM, Vishwakarma RA. Fused pyrimidines as isoform-selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof, US10696688. Granted in US 2020
Bharate SB, Kumar A, Manda S, Joshi P, Bharate SS, Wani A, Sharma S, Vishwakarma RA. Alkylidene Phosphonate esters as P-glycoprotein inducers. US10377781B2, EP3209671. Granted in US, EP

 

 2019
Bharate SB, Kumar A, Manda S, Joshi P, Bharate SS, Vishwakarma RA. N-Substituted beta-carbolinium compounds as potent P-glycoprotein inducers. US10072009

 

 Granted in US 2018
Jain SK, Sidiq T, Meena S, Khajuria A, Vishwakarma RA, Bharate SB. Preparation of tetrahydro-​2H-​pyrano[3,​2-​c]​isochromene-​6-​one analogs for the treatment of inflammatory disorders. US9777014B2, EP3004116, CA2913281 Granted in US, EP, CA

 

 2017-18
Vishwakarma RA, Bharate SB, Bhushan S, Yadav RR, Guru SK, Joshi P. 6-​Aryl-​4-​phenylaminoquinazolines as phosphoinositide 3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. EP3110801B1 Granted in EP 2019
Bharate SB, Kumar A, Bharate JB, Joshi P, Wani A, Mudududdla R, Sharma R, Vishwakarma RA. Polyalkylated acyl and benzoyl-phloroglucinols as potent P-glycoprotein inducers. US10202326B2, EP15774722.1 Granted in US, EP

 

 2019
Vishwakarma R, Jain SK, Bharate SB, Dar AH, Khajuria A, Meena S, Bhola SK, Qazi AK, Hussain A, Sidiq T, Uma Shaanker R, Ravikanth G, Vasudeva R, Patel MK, Ganeshaiah KN. New chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders. US9776989B2, EP2984078

 

 Granted in US, EP

 

 2017
Bharate SS, Kumar V, Singh R, Rani S, Gupta M, Kumar A, Bharate SB, Vishwakarma RA. Sustained release formulations of Crocus sativus. IN201711036084, WO2019077621A1, EP18796784.9, US16753969 Patent licensed to industry 2018
Thompson CM, Bharate SB. Benzothiazole-based pyridinium compounds. US9255091B2

 

 Patent granted in US 2016

Awards / Honours

Awards and Honours

  • Listed among top 2% World’s Scientists (Field: medicinal & biomolecular chemistry) in the analysis done by Stanford University and published by Elsevier (October 2021).
  • Appointed as Editorial Advisory Board Member for ‘Medicinal Research Reviews’ (Wiley, IF 12.94).
  • CSIR Technology Award 2021 Certificate of Merit (Category: Innovation) for the discovery, development and out licensing of Saffron-based nutraceutical product
  • Listed among top 2% World’s Scientists (Field: medicinal & biomolecular chemistry) in a analysis done of Stanford University (PLOS Biology, October 2020).
  • MEDI Young Investigator Award from American Chemical Society 2020
  • OPPI Young Scientist Award 2019
  • CSIR Young Scientist Award 2016
  • NASI-Young Scientist Platinum Jubilee Award 2015
  • RSC – OSDD Ambassador 2014
  • Several Innocentive Awards 2009-2010 (from Innocentive Inc. USA)

 

Professional memberships:

  • Life Member of Chemical Research Society of India (CRSI) – 2020 onwards
  • Honorary membership of American Chemical Society (ACS) (2016-2019) (2020-2021)
  • Member of American Chemical Society (ACS) 2010-2011
  • Member of Royal Society of Chemistry (RSC) – Affiliate member (honorary membership)
  • Life Member of Maharashtra State Pharmacy Council (MSPC)
  • Life Member of Indian Society for Mass Spectrometry (ISMAS)

 

Group

Students

Photo Name Area of Interest  Position
Dr. Venu Sharma Medicinal chemistry of natural products to discover anticancer lead candidates DST Women Scientist
Vijay K. Nuthakki Natural products driven drug discovery for Alzheimer’s disease Project Associate; AcSIR PhD Student
Rinky Raghuvanshi Natural products driven drug discovery for Alzheimer’s disease UGC-SRF; AcSIR PhD Student
Mohit Sharma Rational drug design, and synthesis of potential anti-Alzheimer agents Project Fellow; AcSIR PhD Student
Razia Banoo Rational drug design, and synthesis of potential anti-Alzheimer agents UGC-JRF; AcSIR PhD Student
Deendyal Bhurta Medicinal chemistry of natural products to discover Cdk inhibitors AcSIR PhD Student
Ankita Sharma Natural products driven drug discovery for Alzheimer’s disease AcSIR PhD Student

 

Alumni (PhD completion year) Current affiliation
Ramesh Mudududdla (2016) Postdoc, Monash University, Australia
Rammohan R. Yadav (2016) Scientist at Sci Life Sciences Hyderabad
Sudhakar Manda (2016) Scientist at Aurigene discovery, Bangalore
Rohit Sharma (2017) Assistant Professor, Dr. Y.S. Parmar University, HP, India
Prashant Joshi (2018) Assistant Professor, NMIMS Shirpur, Maharashtra
Abubakar Wani (2019) Postdoc, Washington University, USA
Shreyans K. Jain (2015) Asst Prof,  IIT-BHU Varanasi
Baljinder Singh (2016) Postdoc, Northeastern University Boston, USA
Mohd Shabber (2016) Postdoc, Ohio State University, USA
Rajni Sharma (2017) Research Associate, DRDO
Mohd. Abdullaha (2021) –

Technologies out licensed /
IND applications filed

Technologies out licensed / IND applications filed

  • IIIM-141, nutraceutical product out-licensed to M/S Pharmanza Herbals Pvt Ltd Gujarat (July 2018)
  • IIIM-160 (dual anti-IL6/ antinociceptive botanical) outlicensed to M/S Viridis Biopharma Pvt Ltd Mumbai (June 2021)
  • IIIM-290 (NCE lead for pancreatic cancer), IND approved by DCGI (May 2020)
  • IIIM-160 (phytopharmaceutical lead for rheumatoid arthritis) – IND application filed to DCGI in April 2020
  • Developed the process for synthesis of niclosamide (drug being repurposed for COVID-19).